

**S4 Table.** Parts 1 and 2: treatment-related adverse events (grade  $\geq$  3)

Adverse event	Part 1					Part 2	Total (n=55)
	81 mg (n=5)	201 mg (n=9)	403 mg (n=4)	604 mg (n=4)	685 mg (n=3)	685 mg (n=30)	
<b>Grade 3</b>							
Hypertension	1 (20.0)	3 (33.3)	2 (50.0)	1 (25.0)	0	11 (36.7)	18 (32.7)
Palmar-plantar erythrodysesthesia syndrome	0	0	0	0	1 (33.3)	3 (10.0)	4 (7.3)
Hypokalemia	0	0	0	0	0	3 (10.0)	3 (5.5)
Hypophosphatemia	0	1 (11.1)	0	1 (25.0)	0	1 (3.3)	3 (5.5)
Neutrophil count decreased	0	0	2 (50.0)	0	0	0	2 (3.6)
Platelet count decreased	0	0	1 (25.0)	0	0	1 (3.3)	2 (3.6)
Hypothyroidism	0	0	0	1 (25.0)	0	0	1 (1.8)
Diarrhea	0	0	0	0	0	1 (3.3)	1 (1.8)
Stomatitis	0	0	0	0	0	1 (3.3)	1 (1.8)
Blood bilirubin increased	0	0	0	0	0	1 (3.3)	1 (1.8)
Hypocalcemia	0	1 (11.1)	0	0	0	0	1 (1.8)
Tumor hemorrhage	0	0	1 (25.0)	0	0	0	1 (1.8)
Syncope	0	1 (11.1)	0	0	0	0	1 (1.8)
Dysphonia	0	0	0	0	0	1 (3.3)	1 (1.8)
<b>Grade 4</b>							
Hyponatremia	0	1 (11.1)	0	0	0	0	1 (1.8)
Malignant hypertension	0	1 (11.1)	0	0	0	0	1 (1.8)
<b>Grade 5</b>							
Tumor hemorrhage	0	0	0	0	0	1 (3.3)	1 (1.8)

Values are presented as number (%).